MarketCap
Facebook
X
Telegram
Acorda Therapeutics DIO Ratio | ACOR
Annual DIO Ratio Acorda Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 345 | 188 | 211 | 294 | 284 | 124 | 61.5 | 146 | 143 | 122 | 143 | 133 | 156 | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 345 | 61.5 | 181 |
Quarterly DIO Ratio Acorda Therapeutics
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 395 | 441 | 421 | 370 | - | 127 | 156 | 255 | - | 158 | 213 | 214 | - | 236 | 401 | 603 | - | 317 | 289 | 314 | - | 104 | 85.2 | 147 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 603 | 85.2 | 276 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
91.6 | $ 293.87 | 0.19 % | $ 520 B |  USA |
 |
Alnylam Pharmaceuticals
ALNY
|
43.5 | $ 151.6 | -3.2 % | $ 19.9 B | USA |
 |
Axon Enterprise
AXON
|
98.8 | $ 302.6 | -0.19 % | $ 23.6 B | USA |
 |
Theratechnologies
THTX
|
373 | - | - | $ 83.9 M |  Canada |
 |
Bristol-Myers Squibb Company
BMY
|
68.7 | $ 62.8 | 1.06 % | $ 128 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
570 | - | -3.76 % | $ 3.47 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
221 | $ 4.0 | -6.76 % | $ 48.8 M |  Israel |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
235 | $ 317.26 | 0.99 % | $ 6.14 B | USA |
 |
Eli Lilly and Company
LLY
|
352 | $ 1 432.7 | 1.47 % | $ 1.29 T | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
343 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
CorMedix
CRMD
|
308 | $ 5.37 | -2.1 % | $ 387 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
19.1 K | - | -15.15 % | $ 60.3 M |  Britain |
 |
MannKind Corporation
MNKD
|
430 | $ 4.22 | 0.84 % | $ 1.29 B | USA |
 |
AVEO Pharmaceuticals
AVEO
|
149 | - | - | $ 521 M | USA |
 |
Merck & Co.
MRK
|
142 | $ 147.75 | -0.68 % | $ 370 B | USA |
 |
Moderna
MRNA
|
56.8 | $ 250.79 | -6.77 % | $ 97.6 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
455 | - | - | $ 2.02 B | USA |
 |
Novartis AG
NVS
|
130 | $ 163.39 | -0.18 % | $ 317 B |  Schweiz |
 |
Omeros Corporation
OMER
|
484 | $ 17.3 | -1.48 % | $ 1.1 B | USA |
 |
Puma Biotechnology
PBYI
|
44.7 | $ 8.13 | -3.22 % | $ 407 M | USA |
 |
Pfizer
PFE
|
244 | $ 29.34 | 0.36 % | $ 167 B | USA |
 |
Завод ДИОД
DIOD
|
768 | - | - | - |  Russia |